Aclaris Therapeutics (ACRS) Income from Continuing Operations (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Income from Continuing Operations of 37461000.0 for Q1 2026, down 102.61% year-over-year from 1433988465.84 in Q1 2025, and down 19.61% quarter-over-quarter from 31318000.0 in Q4 2025.
Powered by 
Analysis
Aclaris Therapeutics (ACRS) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Income from Continuing Operations history runs 13 years deep, the most recent figure standing at 37461000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 102.61% year-over-year to 37461000.0; the TTM figure through Mar 2026 stood at 106836000.0 (up 27.77% YoY), while the FY2025 annual figure was 272973000.0, down 106.7% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 37461000.0, down from 31318000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9662000.0 in Q3 2024, with the low at 196982000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 32941000.0 (2023), against an average of 42680705.88.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 349.74% in 2023, then surged 71.08% in 2025.
- Aclaris Therapeutics' Income from Continuing Operations stood at 43799000.0 in 2022, then tumbled by 349.74% to 196982000.0 in 2023, then surged by 45.03% to 108290000.0 in 2024, then jumped by 71.08% to 31318000.0 in 2025, then declined by 19.61% to 37461000.0 in 2026.
- Business Quant data shows ACRS's Income from Continuing Operations at 37461000.0 in Q1 2026, 31318000.0 in Q4 2025, and 19191000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Aclaris Therapeutics | 878.55 Mn | 878.55 Mn | 1.41 Mn | -22.48 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.48 Mn |
| Mar 31, 2026 | -20.68 Mn |
| Dec 31, 2025 | -21.10 Mn |
| Sep 30, 2025 | -15.33 Mn |
| Jun 30, 2025 | -16.39 Mn |
| Mar 31, 2025 | -15.92 Mn |
| Dec 31, 2024 | -97.57 Mn |
| Sep 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -10.99 Mn |
| Mar 31, 2024 | -16.94 Mn |
| Dec 31, 2023 | -1.86 Mn |
| Sep 30, 2023 | -29.26 Mn |
| Jun 30, 2023 | -32.57 Mn |
| Mar 31, 2023 | -29.38 Mn |
| Dec 31, 2022 | -28.51 Mn |
| Sep 30, 2022 | -21.01 Mn |
| Jun 30, 2022 | -21.35 Mn |
| Mar 31, 2022 | -19.66 Mn |
| Dec 31, 2021 | -23.12 Mn |
| Sep 30, 2021 | -20.29 Mn |